Christophe Ginestier

List of Publications by Year in Descending Order

86 papers	13,508 citations	45 h-index	116 g-index
121 ext. papers	14,995 ext. citations	8.4 avg, IF	5.46 L-index

#	Paper	IF	Citations
86	BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells.. *Cell Death and Disease*, **2022**, 13, 96	9.8	1
85	Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin. *Cancers*, **2022**, 14, 2404	6.6	
84	CD95/Fas suppresses NF-B activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism.. *IScience*, **2021**, 24, 103538	6.1	0
83	CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells. *IScience*, **2021**, 24, 103348	6.1	0
82	A stem cell population at the anorectal junction maintains homeostasis and participates in tissue regeneration. *Nature Communications*, **2021**, 12, 2761	17.4	5
81	miRViz: a novel webserver application to visualize and interpret microRNA datasets. *Nucleic Acids Research*, **2020**, 48, W252-W261	20.1	4
80	CD44 regulates epigenetic plasticity by mediating iron endocytosis. *Nature Chemistry*, **2020**, 12, 929-938	17.6	45
79	CD95/Fas and metastatic disease: What does not kill you makes you stronger. *Seminars in Cancer Biology*, **2020**, 60, 121-131	12.7	9
78	Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. *Journal of Clinical Medicine*, **2019**, 8,	5.1	2
77	PH-domain-binding inhibitors of nucleotide exchange factor BRAG2 disrupt Arf GTPase signaling. *Nature Chemical Biology*, **2019**, 15, 358-366	11.7	6
76	Transcriptomic Analysis of Breast Cancer Stem Cells and Development of a pALDH1A1:mNeptune Reporter System for Live Tracking. *Proteomics*, **2019**, 19, e1800454	4.8	4
75	A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. *EMBO Molecular Medicine*, **2019**, 11, e9930	12	12
74	Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. *Oncotarget*, **2018**, 9, 33762-33777	3.3	13
73	The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/Catenin Signaling. *Stem Cell Reports*, **2018**, 11, 1040-1050	8	8
72	miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling. *Cell Reports*, **2017**, 18, 2256-2268	10.6	81
71	A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability. *Nature Medicine*, **2017**, 23, 568-578	50.5	78
70	Salinomycin kills cancer stem cells by sequestering iron in lysosomes. *Nature Chemistry*, **2017**, 9, 1025-1033	17.6	254

69	An iron hand over cancer stem cells. *Autophagy*, **2017**, 13, 1465-1466	10.2	27
68	Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. *Annals of Oncology*, **2017**, 28, 769-776	10.3	32
67	Flick the cancer stem cells switch to turn cancer off. *Molecular and Cellular Oncology*, **2017**, 4, e1319896	1.2	
66	HTS-Net: An integrated regulome-interactome approach for establishing network regulation models in high-throughput screenings. *PLoS ONE*, **2017**, 12, e0185400	3.7	4
65	Breast cancer stem cells programs: enter the (non)-code. *Briefings in Functional Genomics*, **2016**, 15, 186-99	4.9	5
64	Pregnane X-receptor promotes stem cell-mediated colon cancer relapse. *Oncotarget*, **2016**, 7, 56558-56573	5.3	23
63	Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. *Oncotarget*, **2016**, 7, 79428-79441	3.3	8
62	Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling. *Cancer Research*, **2015**, 75, 3373-83	10.1	29
61	Role of microRNA221 in regulating normal mammary epithelial hierarchy and breast cancer stem-like cells. *Oncotarget*, **2015**, 6, 3709-21	3.3	44
60	MicroRNA100 inhibits self-renewal of breast cancer stem-like cells and breast tumor development. *Cancer Research*, **2014**, 74, 6648-60	10.1	58
59	Brief reports: A distinct DNA methylation signature defines breast cancer stem cells and predicts cancer outcome. *Stem Cells*, **2014**, 32, 3031-6	5.8	24
58	Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. *Stem Cell Reports*, **2014**, 2, 78-91	8	656
57	Growth hormone is secreted by normal breast epithelium upon progesterone stimulation and increases proliferation of stem/progenitor cells. *Stem Cell Reports*, **2014**, 2, 780-93	8	35
56	Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib. *PLoS ONE*, **2014**, 9, e104302	3.7	35
55	Aldehyde dehydrogenase and estrogen receptor define a hierarchy of cellular differentiation in the normal human mammary epithelium. *Breast Cancer Research*, **2014**, 16, R52	8.3	40
54	ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. *Cancer Research*, **2013**, 73, 7290-300	10.1	98
53	The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. *Clinical Cancer Research*, **2013**, 19, 6520-31	12.9	112
52	Cellules souches du cancer du sein : prendre le cancer à la racine. *Oncologie*, **2012**, 14, 543-549	1	

51	Cancer stem cell vaccination confers significant antitumor immunity. *Cancer Research*, **2012**, 72, 1853-64	10.1	162
50	Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. *Stem Cells*, **2012**, 30, 1327-37	5.8	97
49	What drives breast cancer heterogeneity: oncogenic events or cell of origin?. *Journal of Pathology*, **2012**, 227, 267-9	9.4	1
48	MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. *PLoS Genetics*, **2012**, 8, e1002751	6	136
47	Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. *Cancer Research*, **2011**, 71, 614-24	10.1	476
46	ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. *EMBO Molecular Medicine*, **2011**, 3, 153-66	12	88
45	Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. *Cancer Research*, **2011**, 71, 3991-4001	10.1	382
44	Correction: Breast Cancer Stem Cells Are Regulated by Mesenchymal Stem Cells through Cytokine Networks: Figure 4.. *Cancer Research*, **2011**, 71, 2407-2407	10.1	1
43	Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. *Clinical Cancer Research*, **2010**, 16, 45-55	12.9	570
42	Targeting breast cancer stem cells: fishing season open!. *Breast Cancer Research*, **2010**, 12, 312	8.3	9
41	Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. *Breast Cancer Research and Treatment*, **2010**, 122, 777-85	4.4	372
40	CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. *Journal of Clinical Investigation*, **2010**, 120, 485-97	15.9	577
39	Retinoid signaling regulates breast cancer stem cell differentiation. *Cell Cycle*, **2009**, 8, 3297-302	4.7	168
38	Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. *PLoS Biology*, **2009**, 7, e1000121	9.7	414
37	Breast cancer stem cells: tools and models to rely on. *BMC Cancer*, **2009**, 9, 202	4.8	94
36	Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. *Cancer Research*, **2009**, 69, 1302-13	10.1	938
35	Getting to the root of BRCA1-deficient breast cancer. *Cell Stem Cell*, **2009**, 5, 229-30	18	21
34	Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. *Cancer Research*, **2009**, 69, 3382-9	10.1	824

33	BRCA1 regulates human mammary stem/progenitor cell fate. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 1680-5	11.5	365
32	Cancer stem cells in breast: current opinion and future challenges. *Pathobiology*, **2008**, 75, 75-84	3.6	142
31	Moesin expression is a marker of basal breast carcinomas. *International Journal of Cancer*, **2007**, 121, 1779-85	7.5	63
30	Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. *Oncogene*, **2007**, 26, 298-307	9.2	71
29	ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. *Oncogene*, **2007**, 26, 7163-9	9.2	47
28	Nectin-4 is a new histological and serological tumor associated marker for breast cancer. *BMC Cancer*, **2007**, 7, 73	4.8	102
27	Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. *Breast*, **2007**, 16, 352-8	3.6	15
26	ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell*, **2007**, 1, 555-67	18	3079
25	Mammary stem cell number as a determinate of breast cancer risk. *Breast Cancer Research*, **2007**, 9, 109	8.3	53
24	Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. *BMC Cancer*, **2006**, 6, 245	4.8	100
23	Prognosis and gene expression profiling of 20q13-amplified breast cancers. *Clinical Cancer Research* , **2006**, 12, 4533-44	12.9	104
22	Gene expression profiling of breast cell lines identifies potential new basal markers. *Oncogene*, **2006**, 25, 2273-84	9.2	425
21	Le tissu microarray outil de recherche et/ou de routine dans le cadre des cancers du sein. *Oncologie*, **2006**, 8, 267-268	1	
20	How to best classify breast cancer: Conventional and novel classifications (Review) **2005**, 27, 1307		3
19	Junctional recruitment of mammalian Scribble relies on E-cadherin engagement. *Oncogene*, **2005**, 24, 4330-9	9.2	165
18	ETV6 gene rearrangements in invasive breast carcinoma. *Genes Chromosomes and Cancer*, **2005**, 44, 103-8	3	25
17	Typical medullary breast carcinomas have a basal/myoepithelial phenotype. *Journal of Pathology*, **2005**, 207, 260-8	9.4	172
16	Comprehensive profiling of 8p11-12 amplification in breast cancer. *Molecular Cancer Research*, **2005** , 3, 655-67	6.6	178

15	Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. *Cancer Research*, **2005**, 65, 767-79	10.1	141
14	How to best classify breast cancer: conventional and novel classifications (review). *International Journal of Oncology*, **2005**, 27, 1307-13	1	9
13	Basal and luminal breast cancers: Basic or luminous? (Review) **2004**, 25, 249		4
12	A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene. *Cancer Research*, **2004**, 64, 6840-4	10.1	170
11	Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. *Oncogene*, **2004**, 23, 1377-91	9.2	265
10	Identification and validation of an ERBB2 gene expression signature in breast cancers. *Oncogene*, **2004**, 23, 2564-75	9.2	101
9	Immunophenotypic analysis of inflammatory breast cancers: identification of an ℞nflammatory signature℞ *Journal of Pathology*, **2004**, 202, 265-73	9.4	150
8	Comparative multi-methodological measurement of ERBB2 status in breast cancer. *Journal of Pathology*, **2004**, 202, 286-98	9.4	58
7	A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene. *Genes Chromosomes and Cancer*, **2003**, 37, 333-45	5	46
6	Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer. *International Journal of Cancer*, **2003**, 107, 854-62	7.5	16
5	TACC1-chTOG-Aurora A protein complex in breast cancer. *Oncogene*, **2003**, 22, 8102-16	9.2	81
4	Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene. *Genes Chromosomes and Cancer*, **2002**, 35, 204-18	5	29
3	Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators. *Oncogene*, **2002**, 21, 5619-30	9.2	56
2	Loss of heterozygosity at microsatellite markers from region p11-21 of chromosome 8 in microdissected breast tumor but not in peritumoral cells **2002**, 21, 989		3
1	Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. *American Journal of Pathology*, **2002**, 161, 1223-33	5.8	133